Drug Trial Radar · NCT00911261
Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
Last checked: Nov 20, 2026Latest source record: Feb 15, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
223
Actual
Start
Aug 2003
Primary completion
Mar 2005
Study completion May 2005
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.
Conditions
- Chronic Pain
- Neuropathic Pain
- Cancer
Interventions
Oxymorphone Extended ReleaseDrug
* Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets * Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets * Treatment will consist of up to 12 months of dosing with Oxymorphone ER.
Primary outcomes
What the sponsor says the trial is designed to measure.
- TolerabilityTime frame: Throughout the study
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.